Celltrion (South Korea)

Recent papers from Celltrion (South Korea)

1. Uncovering the full economic impact of biosimilars: a “would have spent” counterfactual analysis of five reference biologics (infliximab, adalimumab, bevacizumab, rituximab, and trastuzumab) in the United States and Europe, 2016–2025Journal of Medical Economics · 2026
2. Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin® and US-Avastin® in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung CancerBioDrugs · 2026
3. Subcutaneous infliximab in the treatment of patients with perianal fistulizing Crohn’s disease: current evidence and emerging rolesTherapeutic Advances in Gastroenterology · 2026
4. Shared challenges in the management of difficult-to-treat chronic inflammatory diseases: expert perspectivesExpert Opinion on Biological Therapy · 2026
5. Bifidobacterium stercoris KC84 attenuates IBS-D-like symptoms via modulation of serotonin-related pathways and dendritic cell-mediated IFN-β inductionCurrent Research in Microbial Sciences · 2026
6. Impact of Immunogenicity on Clinical Outcomes in Patients With Moderate‐to‐Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY TrialsUnited European Gastroenterology Journal · 2026
7. Abstract 4438: A novel synergistic dual-payload TROP2 ADC (CTPH-03) delivering enhanced safety by increased MTDCancer Research · 2026
8. Abstract 1698: A novel synergistic dual-payload FRα ADC (CTPH-08) that can potentially offer benefits for low IHC+ ovarian cancer patients by improving MTD and MEDCancer Research · 2026
9. Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn’s Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD TrialAdvances in Therapy · 2026
10. Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trialsInflammatory Bowel Diseases · 2026
11. Determination of correlation of clearance with clinical outcomes for inflammatory bowel diseaseWorld Journal of Gastroenterology · 2026
12. Genetic and biochemical profile of patients with severe traumatic brain injury: a prospective longitudinal observational tertiary care hospital-based studyJournal of Neurosurgical Sciences · 2026
13. Pharmacokinetics and safety of candidate biosimilar CTP55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, phase I studyExpert Opinion on Investigational Drugs · 2026
14. P0832Recapturing disease control with subcutaneous infliximab after a drug holiday following intravenous infliximab induction: A post hoc analysis of LIBERTY-CD and -UC studiesJournal of Crohn s and Colitis · 2026
15. Commensal microbe-derived butyrate enhances T follicular helper cell function to boost mucosal vaccine efficacySHILAP Revista de lepidopterología · 2026
16. Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn’s Disease: A Systematic Literature Review and Network Meta-AnalysisAdvances in Therapy · 2026
17. Discovery and Preclinical Evaluation of PBX-7016, a Methylenedioxy-Camptothecin Payload for Antibody-Drug Conjugates with Enhanced Therapeutic PotentialJournal of Medicinal Chemistry · 2025
18. Efficacy and safety of pioglitazone versus dapagliflozin as an add-on to metformin and alogliptin combination therapy: the EPIDOTE studyScientific Reports · 2025
19. A retrospective, multinational, cross-sectional survey of real-world outcomes for patients with axial spondyloarthritis receiving subcutaneous infliximabBMC Rheumatology · 2025
20. Fine-Tuning of Label-Free Single-Cell Proteomics Workflows2025